Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Neumora Therapeutics has received a consensus recommendation of "Hold" from nine research firms, with one sell rating, five hold ratings, and three buy ratings.
• Institutional investors have significantly increased their stakes in Neumora Therapeutics, with Wells Fargo boosting its holdings by 23% and Invesco by 254.1% in the last quarter.
• The company reported a loss of $0.33 earnings per share for the last quarter, which was better than the consensus estimate of a loss of $0.38.

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has been assigned an average rating of "Hold" from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $7.1429.

Several equities analysts recently issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, May 13th. Mizuho upped their price target on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th.

Neumora Therapeutics Trading Down 2.7%

Shares of NMRA traded down $0.0450 during trading hours on Friday, reaching $1.5950. The stock had a trading volume of 135,536 shares, compared to its average volume of 2,064,577. The company has a market cap of $258.31 million, a P/E ratio of -1.02 and a beta of 2.91. Neumora Therapeutics has a 52 week low of $0.6110 and a 52 week high of $17.1874. The company has a quick ratio of 10.54, a current ratio of 10.54 and a debt-to-equity ratio of 0.11. The firm has a 50-day moving average of $1.32 and a 200 day moving average of $1.16.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.05. On average, sell-side analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NMRA. Wells Fargo & Company MN boosted its position in Neumora Therapeutics by 23.0% during the 4th quarter. Wells Fargo & Company MN now owns 70,653 shares of the company's stock worth $749,000 after acquiring an additional 13,196 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Neumora Therapeutics by 254.1% in the 4th quarter. Invesco Ltd. now owns 49,249 shares of the company's stock valued at $522,000 after acquiring an additional 35,342 shares in the last quarter. Legal & General Group Plc increased its position in shares of Neumora Therapeutics by 526.4% in the fourth quarter. Legal & General Group Plc now owns 59,842 shares of the company's stock valued at $634,000 after acquiring an additional 50,289 shares during the last quarter. Barclays PLC raised its holdings in Neumora Therapeutics by 29.1% during the fourth quarter. Barclays PLC now owns 166,822 shares of the company's stock worth $1,767,000 after acquiring an additional 37,612 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Neumora Therapeutics during the fourth quarter worth about $231,000. 47.65% of the stock is currently owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.